Source - SMW
ImmuPharma has been asked to open a new site in Mauritius as part of the phase III clinical trial of Lupuzor, the group's lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.

 Cap Research, a leading contract research organisation in Mauritius, will be leading the trial and patient recruitment. 

It is anticipated that around 30 Lupus patients will start recruitment within this new site over the next few weeks as part of the ongoing 200 patient Lupuzor trial.   ImmuPharma says that Mauritius, with a population of around 1.2 million, is prevalent to a high proportion of Lupus sufferers, with approximately 3000 current Lupus patients. 

In May 2016, Prof. Sylviane Muller, inventor of Lupuzor, was invited to visit Mauritius as a guest of 'Lupus Alert', the country's pre-eminent Lupus foundation which has been following the progress of Lupuzor since the commencement of its pivotal phase III trial.

Over one week,  Muller had an audience with Ameenah Gurib-Fakim, Mauritius' President and a prominent scientist.

 Muller also met with high ranking government officials, leading Rheumatologists and the Ministry of Health, which is responsible for approving clinical trials in the country, delivering presentations. TV/radio interviews on Lupuzor were also conducted. Discussions focused primarily on the government's strong interest for ImmuPharma to include Mauritius in its current pivotal phase III trial for Lupuzor.

Chairman Tim McCarthy said: "We are delighted to have been requested by the Mauritian government and the country's leading Lupus specialists to participate in our trial. 

"Mauritius with its high proportion of Lupus sufferers clearly highlights how necessary an effective Lupus therapy such as Lupuzor is needed for such a debilitating disease. We look forward to providing further positive updates on our Lupuzor Phase III study as it progresses further through this year and into 2017."

At 8:21am: (LON:IMM) ImmuPharma PLC share price was +0.75p at 34.75p